Figures & data
Table 1 Microdilution minimum inhibitory concentration and minimum effective concentration (μg/mL) for the clinically available echinocandins against Candida and Aspergillus species (CitationTawara et al 2000; CitationArikan et al 2003; CitationEspinel-Ingroff 2003; CitationHeyn et al 2005; CitationOstrosky-Zeichner et al 2005; CitationPfaller et al 2006; CitationMesser et al 2006; CitationPfaller et al 2006; CitationPfaller and Diekema 2007; CitationGarcia-Effron et al 2008a)
Table 2 Amino acid sequences and nucleotide changes in susceptible and resistant isolates from various Candida species reported in the literature
Figure 1 Linear profile of the Fks1p subunit in Candida albicans and loci containing amino acid substitutions associated with reduced echinocandin susceptibility. Adapted with permission from CitationPark S, Kelly R, Kahn JN, et al. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother, 49:3264–73, and from CitationBalashov SV, Park S, Perlin DS. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother, 50:2058–63. Copyright © 2005 and 2006 American Society for Microbiology.
Table 3 Mean micafungin pharmacokinetic parameters (±SD) by different age groups and different doses in pediatric and adult patients (CitationHebert et al 2005b; CitationHiemenz et al 2005; CitationSeibel et al 2005; CitationHeresi et al 2006)
Figure 2 Response rates of antifungal agents in clinical trials of invasive candidiasis. FLC: fluconazole, AMB: amphotercin B deoxycholate, CFG: caspofungin, AFG: anidulafungin, MFG: micafungin, LAMB: liposomal amphotericin B, MFG 100: micafungin 100 mg, MFG 150: micafungin 150 mg (CitationRex et al 1994; CitationMora-Duarte et al 2002; CitationKullberg et al 2005; CitationKuse et al 2007; CitationPappas et al 2007; CitationReboli et al 2007).
